Publication date: Dec 16, 2019
The World Health Organization (WHO) has defined more than 130 distinct central nervous system (CNS) tumor entities, of which glioblastoma is the most fatal primary brain tumor. However, the correlation of the molecular signatures of glioblastoma with clinical significance for precision medicine is not well-known. How, and to what extent these variants may affect clinical decision making remains uncertain. Here, we evaluate 48 glioblastomas submitted for testing using the JAX ActionSeq? Next-generation sequencing (NGS) panel. We identified 131 clinically significant variants (Tier I and II) across 30 of the 212 genes (14%). TP53, EGFR, PTEN, IDH1 were the most commonly mutated genes; EGFR, CDK4 amplifications, and CDKN2A deletion were the most frequently detected copy-number alterations. CDK4/6 and PI3K inhibitors were among the most commonly reported drug class with FDA approved therapies and investigational therapies, which is consistent with the frequencies of these genes in our cohort. Overall, our study established the molecular profiles of glioblastoma based on the 2017 joint consensus guidelines by AMP/ASCO/CAP and provides the potential implications for targeted therapeutic options currently available.
Nie, Q., Hsiao, M.C., Chandok, H., Rowe, S., Prego, M., Meyers, B., Omerza, G., Hesse, A., Uvalic, J., Soucy, M., Bergeron, D., Peracchio, M., Burns, S., Kelly, K., Rueter, J., and Reddi, H.V. Molecular profiling of CNS tumors for the treatment and management of disease. 06000. 2019 J Clin Neurosci.
|disease||MESH||primary brain tumor|
- Mutation Yield of a Custom 212-Gene Next-Generation Sequencing Panel for Solid Tumors: Clinical Experience of the First 260 Cases Tested Using the JAX ActionSeq™ Assay.
- Molecular characterization of lung adenocarcinoma from Korean patients using next generation sequencing.
- Discovery of actionable genetic alterations with targeted panel sequencing in children with relapsed or refractory solid tumors.
- Molecular Evolution of IDH Wild-Type Glioblastomas Treated With Standard of Care Affects Survival and Design of Precision Medicine Trials: A Report From the EORTC 1542 Study.
- Multiplatform biomarker identification using a data-driven approach enables single-sample classification.
- Identifying Biomarkers to Pair with Targeting Treatments within Triple Negative Breast Cancer for Improved Patient Stratification.